Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Prime Medicine (PRME) Enterprise Value (2021 - 2025)

Historic Enterprise Value for Prime Medicine (PRME) over the last 5 years, with Q3 2025 value amounting to -$208.4 million.

  • Prime Medicine's Enterprise Value fell 2215.87% to -$208.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$208.4 million, marking a year-over-year decrease of 2215.87%. This contributed to the annual value of -$187.4 million for FY2024, which is 6129.35% down from last year.
  • Latest data reveals that Prime Medicine reported Enterprise Value of -$208.4 million as of Q3 2025, which was down 2215.87% from -$98.3 million recorded in Q2 2025.
  • Over the past 5 years, Prime Medicine's Enterprise Value peaked at -$92.2 million during Q2 2022, and registered a low of -$286.1 million during Q4 2022.
  • Over the past 5 years, Prime Medicine's median Enterprise Value value was -$170.6 million (recorded in 2024), while the average stood at -$177.8 million.
  • Data for Prime Medicine's Enterprise Value shows a peak YoY increase of 5937.84% (in 2023) and a maximum YoY decrease of 11815.28% (in 2023) over the last 5 years.
  • Prime Medicine's Enterprise Value (Quarter) stood at -$253.7 million in 2021, then fell by 12.78% to -$286.1 million in 2022, then surged by 59.38% to -$116.2 million in 2023, then plummeted by 61.29% to -$187.4 million in 2024, then dropped by 11.19% to -$208.4 million in 2025.
  • Its last three reported values are -$208.4 million in Q3 2025, -$98.3 million for Q2 2025, and -$140.3 million during Q1 2025.